ARTICLE | Emerging Company Profile

Sirnaomics: Two is better than one

March 15, 2010 7:00 AM UTC

Current treatments for wound healing after surgery do not adequately address reduction in scar formation, and compounds in development may not address enough of the targets involved in the process, according to Sirnaomics Inc. The biotech hopes that by using siRNA to inhibit two proteins involved in scar formation, it will have an advantage.

According to co-founder and VP of Discovery Research David Evans, compounds in development to reduce scarring after surgery focus on the role of a single protein, which may not adequately reduce scar formation...